Clinical trial
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Study timeline
Study start (actual)2023-04-18Date precision: day
Registry last updated2026-07-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced or Metastatic Solid Tumorsunresolved
Breast Cancerunresolved
Ovarian Cancerunresolved
Prostate Cancerunresolved
Endometrial Cancerunresolved
Colorectal Cancerunresolved
Head and Neck Cancersunresolved
NSCLCunresolved
Interventions
IDE-161DRUG
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
IDEAYA Bioscienceslead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
New YorkNew York, United States2PhiladelphiaPennsylvania, United States2HoustonTexas, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05787587 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.